Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Eledon Pharmaceuticals, Inc.

NASDAQ: ELDN · Life Sciences · 2 alerts · CIK 1404281

Share price
$1.97Close, Nov 16
Market cap
$166M
Shares outstanding
84.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Eledon Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:32 PM ET 10-Q
Financial Results

Eledon Pharmaceuticals Q3 2026 Results: Net Loss of $3.93M, Loss Narrows

For the nine months ended September 30, 2026, Eledon Pharmaceuticals reported a net loss of $74.6 million, a significant increase from the $35.2 million loss in the prior year period, primarily driven by a $11.6 million unfavorable change in the fair value of warrant liabilities. Total assets decreased to $106.6 million from $169.0 million at year-end 2025, reflecting a reduction in cash and short-term investments used to fund ongoing research and development operations.

Key figure
Net loss $3.93M
4:11 PM ET 8-K
Financial Results

Eledon Pharmaceuticals Financial Results

Eledon Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $69.7 million and progress in its tegoprubart clinical program. The company remains on track to initiate its global Phase 3 LEGACY trial in kidney transplantation in Q4 2026 and recently received FDA Fast Track designation for the candidate.

Term
Q3 2026

“We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end.”

David-Alexandre C. Gros, M.D., Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.